SEC Form 4 · accession 0001209191-18-062950
ENDRA Life Sciences Inc. · NDRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Milos Thornton
Officer — Chief Technology Officer
Period of report
Dec 13, 2018
Accepted (ET)
Dec 17, 2018 · 4:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001681682
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $2.25 | Dec 13, 2018 | A | 125,000 | A | — | Dec 13, 2026 | Common Stock | 125,000 | 125,000 | D |
Explanation of responses
- F1These Stock Options become exercisable in three equal annual installments beginning on December 13, 2019.